Inhibition of inflammation using α 7 receptor-binding...

Details Inhibition of inflammation using α 7 receptor-binding... Inhibition of inflammation using α 7 receptor-binding...

2007-09-25

2007-09-25

Marschel, Ardin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S277000, C514S183000, C514S001000

Reexamination Certificate

active

10729427

ABSTRACT:
Methods for inhibiting an inflammatory cytokine cascade in a patient are provided. The methods are directed to treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an α7 nicotinic receptor.

REFERENCES:
patent: 5741802 (1998-04-01), Kem et al.
patent: 5902814 (1999-05-01), Gordon et al.
patent: 5977144 (1999-11-01), Meyer et al.
patent: 5998429 (1999-12-01), Macor et al.
patent: 6054434 (2000-04-01), Kropp et al.
patent: 6110914 (2000-08-01), Phillips et al.
patent: 6232319 (2001-05-01), Marazano et al.
patent: 6369224 (2002-04-01), Phillips et al.
patent: 6407095 (2002-06-01), Lochead et al.
patent: 6432975 (2002-08-01), Schmitt et al.
patent: 6441049 (2002-08-01), Reitz et al.
patent: 6479172 (2002-11-01), Hu et al.
patent: 6479510 (2002-11-01), Myers et al.
patent: 6486172 (2002-11-01), Myers et al.
patent: 6492385 (2002-12-01), Myers et al.
patent: 6492386 (2002-12-01), Myers et al.
patent: 6500840 (2002-12-01), Myers et al.
patent: 6538003 (2003-03-01), Galli et al.
patent: 6552012 (2003-04-01), Peters et al.
patent: 6562816 (2003-05-01), Wishka et al.
patent: 6569865 (2003-05-01), Eifion
patent: 6599916 (2003-07-01), Myers et al.
patent: 6610713 (2003-08-01), Tracey
patent: 6635645 (2003-10-01), Lochead et al.
patent: 6838471 (2005-01-01), Tracey
patent: 2002/0016344 (2002-02-01), Tracey
patent: 2002/0040035 (2002-04-01), Myers et al.
patent: 2002/0086871 (2002-07-01), O'Neill et al.
patent: 2003/0105089 (2003-06-01), Wishka et al.
patent: 2003/0119837 (2003-06-01), O'Neill et al.
patent: 2003/0130305 (2003-07-01), Walker et al.
patent: 2003/0149065 (2003-08-01), Loch, III et al.
patent: 2003/0153595 (2003-08-01), Walker et al.
patent: 2003/0176416 (2003-09-01), Peters et al.
patent: 2003/0176702 (2003-09-01), Walker et al.
patent: 2002-030084 (2002-01-01), None
patent: WO96/06098 (1996-02-01), None
patent: WO97/30998 (1997-08-01), None
patent: WO99/10338 (1999-03-01), None
patent: WO 01/85727 (2001-11-01), None
patent: WO 02/44176 (2002-06-01), None
patent: WO 02/057275 (2002-07-01), None
patent: WO 03/032897 (2003-04-01), None
patent: WO 03/078431 (2003-09-01), None
Borovikova et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Letter to Nature 2000; 405:458-462.
Moreland et al. Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein. The New England Journal of Medicine 1997:337: 141-147.
Shimohama et al. Nicotinic alpha7 receptors protect against glumate neurotoxicity and neuronal ischemic damage. Brain Research 779 (1998) 359-363.
Nanri et al. GTS-21, a Nicotnic Agonist, Attenuates Multiple Infarctions and Cognitive Deficit Caused by Permanent Occlusion of Bilateral Common Carotid Arteries in Rats. Jpn. J. Pharmacol, 78, 463-469 (1998).
Nanri et al. Protective Effect of GTS-21, a Novel Nicotinic Receptor Agonist, on Delayed Neuronal Death Induced by Ischemia in Gerbils. Jpn. J. Pharmacol 76, 23-29 (1998).
Pavlov, V.A., et al., “The Cholinergic Anti-Inflammatory Pathway: A Missing Link in Neuroimmunomodulation,”Molecular Medicine, 9(5-8): 125-134 (2003).
Wang, et al., “Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation,”Nature, pp. 1-4 (2002).
Borovikova, et al., “Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin,”Nature, 405: 458-462 (2000).
Tracey, Kevin J., et al., “Mind over immunity,”FASEB J., 15(9): 1575-1576 (2001).
Meyer, Edwin M., et al., “3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat α7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner,”Brain Res., 768(1-2): 49-56 (1997).
Alkondon, M., et al., “Choline is a Selective Agonist of α7 Nicotinic Acetylcholine Receptors in the Rat Brain Neurons,”Eur. J. Neurosci., 9(12): 2734-2742 (1997).
Levin, E.D., et al., “AR-R17779, an α7 nicotinic agonist, improves learning and memory in rats,”Behav. Pharmacol., 10(6-7): 675-680 (1999).
Kem, William R. “The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21),”Behav. Brain Res., 113: 169-181 (2000).
Broad, Lisa M., et al., “PSAB-OFP, a selective α7 nicotinic receptor agonist, is also a potent agonist of the 5-HT, receptor,”Eur. J. Pharmacol., 452(2): 137-1 44 (2002).
Francis, Michael M., et al., “Specific Activation of the α7 Nicotinic Acetylcholine Receptor by a Quaternary Analog of Cocaine,”Mol. Pharmacol., 60(1): 71-79 (2001).
Mullen, George, et al., “(−)-Spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin-2′-one], a Conformationally Restricted Analogue of Acetylcholine, Is a Highly Selective Full Agonist at the α7 Nicotinic Acetylcholine Receptor,”J. Med. Chem., 43(22): 4045-4050 (2000).

Affiliated with

Also associated with

Rating

Inhibition of inflammation using α 7 receptor-binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of inflammation using α 7 receptor-binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of inflammation using α 7 receptor-binding... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3725277